Using Stability Prior Knowledge From ‘Like-molecules’ to Determine Shelf-life

CASSS-Europe CMC Strategy Forum
24 January 2022
Outline

• Introduction
  • Why we need predictive Stability Modelling?

• Types of Stability Model under Development
  • Pooling of ‘like-molecules’
  • Bayesian Analysis
  • Artificial Intelligence (AI) Machine Learning Models

• Comparison of Modelling Methodologies

• Regulatory Landscape & ICH Stability Guideline Revision
Predictive Stability Capability can have a Favorable Impact on the Entire Product Lifecycle

- **Pre-Pivotal**
  - Molecule Assessment
  - Clinical Shelf-life Assignment
  - Pick winners
  - Accelerate progression to clinical trials
  - Reduce clinical scrap

- **Pivotal**
  - Commercial Formulation Development
  - Stability & Comparability
  - Pick winners
  - Streamline experiments

- **Filing**
  - Commercial Shelf-life Assignment
  - Stability Trending
  - Streamline experiments
  - Accelerate progression to MA
  - Accelerate MA to submission and launch
  - Reduce scrap because of expiry

- **Commercial**
  - Stability & Comparability
  - Commercial Shelf-life Assignment
  - Stability Trending
  - Excursion
  - Be prepared for the unplanned journey of DP
  - Support post-approval changes

- **Lifecycle Management**
  - Pick winners
  - Streamline experiments
  - Accelerate progression to MA
  - Reduce clinical scrap
  - Provide real-time stability forecast
  - Be prepared for the unplanned journey of DP
  - Support post-approval changes
Predictive Stability Modelling using Prior Knowledge

• Focus modelling on the Stability-indicating attributes that limit shelf-life

• Accurate, empirical modelling methodologies to predict stability profile – shelf-life
  • Kinetic analysis, e.g. Arrhenius, Advanced Kinetic Modelling
  • Prior knowledge methodologies:
    • Pooling of Prior Knowledge from ‘Like-molecules’
    • Stability Models using Bayesian Statistics
      • Weighting of prior knowledge using the Power Prior
    • Artificial Intelligence Machine Learning prediction models using prior knowledge
    • Clustering to quantify similarity of prior knowledge to inform the Bayesian Power Prior
Selecting Stability Prior Knowledge From ‘Like-molecules’

- What is a ‘like-molecule’?
- Possible criteria to consider
- Which criteria are important for the stability profile?
- Which criteria are relevant for the model being used?

Criteria for Prior Knowledge Molecules Should Focus on Molecule Characteristics that Impact the Attribute Stability Profile

Criteria Considerations
- Therapeutic Modality
- Storage Conditions
- Container Closure
- Formulation
- Test Methods
- Manufacturing Process
- Stability Data to shelf-life
Pooling of ‘Like-molecules’: A Quality by Design Approach

Pooling of ‘like-molecule’ stability data for shelf-life setting extends from:
- EMA Prior Knowledge workshop, 2017
- EMA/FDA accelerated procedures CMC workshop, 2018

The Modelling of Stability Prior Knowledge approach:
- Reference data sets for ‘like molecules’ CQAs
- Data may be normalised for y-intercept
  • It is the trend (slope) that is important
- Non-linear kinetics may be empirically transformed
- Tolerance intervals (TI) for stability-indicating attributes
- Appropriate specification & internal stability limits
  • Aided by a patient-centric specification approach
- TI intersections with stability limits determine shelf-life
- Lowest ‘attribute’ intersect used as product shelf-life

When a new product meets pre-determined criteria, the modelled shelf-life can be applied

Prior knowledge provides a scientific basis to extending shelf-life beyond product-specific, long-term stability data
Liquid Drug Product Attributes Trend Within Limits

- Stability profiles may trend through 36 months
  - No TI intersections with stability limits within 36m
  - 36 months shelf-life assigned

- CEX-HPLC data are normalised:
  - It is the trend that is important

- HMW species data are transformed for linearity

- Stability levels reflect phase appropriate clinical specification

Data from 5 products meeting selection criteria

Claimed shelf-life is highly dependent on the attribute specification
Prior Knowledge and Bayesian Statistics

Bayesian Statistics

An alternative approach to ‘conventional’ frequentist statistics
- Incorporates prior belief (knowledge) gained from experience
- Can help minimize the effect of very small sample sizes
- Improve the precision of our statistical estimates

• Helps overcome the central problem in CMC acceleration of limited batch history

When applied to stability testing
- Increase accuracy of stability profile prediction
- Facilitates determination of a viable shelf-life and establishment of specification acceptance criteria

Thomas Bayes 1702 - 1761
Initial Bayesian Model for %HMW Species: Titrating the Power Prior

- 7 lots of ‘test’ product
  - Open circles
  - Reduced data set
- 4 Prior Knowledge products (8 to 11 lots each)
- Tolerance intervals for test product decreases with increasing weighting for the prior knowledge
- Comparison of Frequentist and Bayesian methods
  - Each prior knowledge molecule had the same Power Prior value (0.5)
  - Includes a dispersion effect

Adding prior knowledge to a reduced dataset can approach the full dataset, by using Bayesian

A Little Prior Knowledge Can Have Significant Impact on Tolerance Bounds
Titrating Prior Knowledge & Varying the Power Prior

Upper Tolerance Intervals (UTL) from the model simulations:

- $a = 0, 0.025, 0.05, 0.075, 0.1, 0.2, 0.3, 0.4, 0.5$
- Full, 0.5 and 0.25 prior knowledge data
  - No dispersion effect
  - Beta distribution
  - Linear regression
  - Monte Carlo analysis

How much prior knowledge is optimal?

Next:
- Non-linear kinetics
- Assess Power Prior through ‘clustering’ analysis of like-molecules

<table>
<thead>
<tr>
<th>Amount of Prior Knowledge</th>
<th>Upper TI prediction @ 36m when $a = 0.5$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full dataset</td>
<td>1.2</td>
</tr>
<tr>
<td>0.5 dataset</td>
<td>1.3</td>
</tr>
<tr>
<td>0.25 dataset</td>
<td>1.4</td>
</tr>
</tbody>
</table>

The Model can Empirically Balance the Amount of Data or the Power Prior for Accurate Predictions that Approach Known Molecule Datasets.
Why Develop an Artificial Intelligence, Machine Learning-driven approach?

AI is a critical capability of digital innovation and can provide answers to critical business questions.

- AI can help us remove traditional constraints that restrict our ability to accelerate our timelines
  - Ability to learn complex relations, patterns from data
  - Predict future outcome with high accuracy

Clean, contextual, integrated data is required to train the model.

- Stability data across molecules as prior knowledge considers multiple variables / differences.
- By evaluating the significance of each variable on the stability profile, the number of dimensions can be reduced to those of high impact.

AI is a critical capability of digital innovation and can provide answers to critical business questions.
Data Selection for the Machine Learning Stability Model

Prior Knowledge Molecules have Visually Similar Rates of %HMW Species Formation

Data extraction

- 7 Prior Knowledge Products
- 1 ‘Hold-out’ product
- 1 ‘New’ molecule

Filtered data

- Product type: Liquid
- Temperature: 5 °C
- Measured attributes: %HMW
- Method: SE-HPLC

Not a comprehensive list
Various algorithms were initially tested as prototype models for prediction accuracy using a test product.

- Selected a neural network algorithm

**Structure of a neural network model is defined by hyperparameters:**

- Hidden layers size
- Number of hidden layers
- Batch size
- Loss function
- Early stopping criteria

Values determined based on iterative training
AI Model Training, Validation and Verification

- A ‘Leave One Product Out’ process was used to validate the machine learning model.
  - A form of K-fold cross-validation
  - Iteratively optimises combinations of hyperparameters
  - Each iteration validates inclusion of each product data set.
  - Hyperparameters are weighted to empirically fit known data from the ‘hold-out’ set – to 95% CI
  - A ‘hold-out’ product was not included in the model training data set, for use in testing the final model accuracy.
  - Model validated for accuracy of prediction from the ‘hold-out’ molecule

- Future refinement could be inclusion of higher temp stability data.
- The model is verified as stability data for the new product are obtained

Training by ‘Leave One Out’ Avoids Overfitting of the Model to any Particular Product

Derived from Biophorum “Industry feedback on DMKA questions to critical GxP AI/ML applications”, 2021
Machine Learning Model Performance Results

Model Accuracy from Known Data

Prediction at 36 months

The Prediction can Support a Stability Specification and/or Product Shelf-life
Mean Shift Clustering to Measure Similarity of Molecules

The prior knowledge data were used for similarity modelling by Mean-shift Clustering to measure the degree of ‘likeness’ between the prior knowledge molecules and the ‘New’ Molecule.

- Molecule features (variables) summed by ‘Principal Component Analysis’.
- Some clustering of the prior knowledge molecules is evident.
- Prior knowledge molecules are more or less distant from the ‘New’ Molecule = degree of similarity.

Clustering Analyses Could Provide Objective Values for the Bayesian Power Prior
## Comparison of Predictive Stability Modelling Tools using Prior Knowledge

<table>
<thead>
<tr>
<th>Methodology</th>
<th>Extrapolation</th>
<th>Similarity</th>
<th>Validation</th>
<th>Verification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pooling Data</td>
<td>No (transposition)</td>
<td>Criteria</td>
<td>e.g. ANCOVA</td>
<td>Yes</td>
</tr>
<tr>
<td>Bayesian</td>
<td>Yes</td>
<td>Power Prior</td>
<td>TBD</td>
<td>Yes</td>
</tr>
<tr>
<td>Machine Learning</td>
<td>Yes</td>
<td>Algorithm</td>
<td>Hold out product</td>
<td>Yes</td>
</tr>
</tbody>
</table>
Regulatory Landscape for Predictive Stability Modelling

EMA CMC Toolbox for PRIME and certain products meeting an ‘unmet’ medical need

ICH Stability Guidance:

- Update to current science and to align with more recent QbD and risk management ICH guidelines
  - Recognition of alternative sources of stability knowledge to set shelf-life beyond traditional, long-term stability data

- Science & Risk-based approaches to accelerate CMC are not described, e.g. modelling, prior knowledge

- Guidance considered as too prescriptive and interpretations too narrow

- Confusion on elements of the Q1 series that apply to biologicals

- Guidance for newer therapeutic modalities is lacking

- Identified gaps include:
  - In-use stability
  - Short-term end user stability
  - Integral drug-device combination (iDDC) products
  - Integrated Stability Profiling – ‘end-to-end’ stability

ICH Q1/5C IWG formed, targeting Concept paper by end October

Revision of ICH Stability Guidelines is Hoped to ‘Open the Door’ to Predictive Stability Modelling, Generally.